CCG
BMY.RT

Cypress Capital Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Cypress Capital Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,724
Closed -$14K – 295
2020
Q4 		$14K Sell
20,724
-450
-2% -$959 ﹤0.01% 266
2020
Q3 		$47K Sell
21,174
-666
-3% -$1.9K 0.01% 253
2020
Q2 		$78K Sell
21,840
-9,257
-30% -$33.4K 0.01% 240
2020
Q1 		$118K Sell
31,097
-3,292
-10% -$10.8K 0.03% 200
2019
Q4 		$104K Buy
+34,389
New +$89.4K 0.02% 238

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Cypress Capital Group's BMY.RT Position: Q1 2021 in Review

Cypress Capital Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 20,724 shares — an estimated $14K sold.

Cypress Capital Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $118K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Cypress Capital Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Cypress Capital Group sold 20,724 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $14K.
  • Cypress Capital Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Cypress Capital Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $118K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Cypress Capital Group's 13F filing for Q1 2021, filed 14 Apr 2021.